<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03065465</url>
  </required_header>
  <id_info>
    <org_study_id>OVESCO</org_study_id>
    <nct_id>NCT03065465</nct_id>
  </id_info>
  <brief_title>Standard Endoscopic Hemostasis Versus OVESCO Severe Non-variceal UGI Hemorrhage</brief_title>
  <official_title>Randomized Controlled Trial (RCT) of Standard Endoscopic Hemostasis Compared to OVESCO for Severe Non-variceal UGI Hemorrhage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CURE Digestive Diseases Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VA Greater Los Angeles Healthcare System</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>CURE Digestive Diseases Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary specific aim is to perform a randomized controlled trial (RCT) to compare the
      rebleeding rates and other clinical outcomes of severe, refractory or recurrent non-variceal
      upper GI hemorrhage (NVUGIH) with a new over-the-scope hemoclipping device (OVESCO) versus
      standard endoscopic hemostasis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Upper GI Hemorrhage (UGIH) causes significant morbidity and mortality, although endoscopic
      hemostasis has revolutionized management of these patients. Despite standard endoscopic
      treatment and high dose proton pump infusions, 27% of patients in referral hospitals with
      upper gastrointestinal bleeding (UGIB) from ulcers or other non-variceal UGI lesions (NVUGI)
      have refractory or recurrent bleeding in a recent RCT by our group. Potential risk factors
      for NVUGI bleeding lesions were large ulcers (≥ 15 mm), fibrotic base, Dieulafoy's lesions,
      anastomotic ulcers, coagulopathies, cirrhosis, severe co-morbidities, and residual arterial
      blood flow under stigmata after endoscopic hemostasis. Such patients with severe rebleeding
      after standard endoscopic hemostasis usually required angiography (by interventional
      radiologists-IR) or surgery for definitive hemostasis. A new, large, FDA approved,
      over-the-scope hemoclipping device (OTSC® System OVESCO Endoscopy, Tübingen, Germany) can
      capture larger amounts of tissue and larger underlying arteries than standard hemoclips and
      potentially could improve endoscopic hemostasis of such bleeding lesions.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rebleeding rate of non-variceal focal UGI lesions</measure>
    <time_frame>Outcome measure will be assessed at 30 days after participants are enrolled</time_frame>
    <description>The investigators will compare the rebleeding rate at 30 days follow up in the two treatment groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Obliteration rates of underlying arterial blood flow (detected by Doppler endoscopic probe)</measure>
    <time_frame>Outcome measure will be assessed at 30 days after the endoscopy treatment is completed</time_frame>
    <description>The investigators will use the Doppler endoscopic probe to measure the blood flow before and after the application of over-the-hemoclipping device and standard endoscopic hemostasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of surgery or IR, complications, cross-over to other endoscopic treatment and death</measure>
    <time_frame>Outcome measure will be assessed at 30 days after participants are enrolled</time_frame>
    <description>The investigators will compare the rates of surgery or IR, complications, and death at 30 days for the two treatment groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Upper Gastrointestinal Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Standard endoscopic treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>For those assigned to the standard endoscopy group, endoscopic hemostasis will be performed using usual Center for Ulcer Research and Education (CURE) hemostasis therapy for the focal GI lesions: injection of dilute (e.g. 1:20,000) epinephrine (in 1-2 cc aliquots in 4 quadrants next to the stigmata of recent hemorrhage - SRH), coaptive coagulation with multipolar electrocautery (MPEC) probe, and/or standard through the endoscope hemoclips along the course of the underlying artery as detected by Doppler endoscopic probe (DEP). Hemostasis will be performed until active bleeding stops and/or the SRH is obliterated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Over-the-scope hemoclipping device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For those assigned OTSC, the device will be used according to manufacturer instructions. Once the endoscopic diagnosis is made, the endoscope will be removed and affixed with the OTSC of appropriate size for the endoscope and the lesion in question. The endoscope will be re-introduced to the bleeding site. The SRH will be centered in the field of view and within the cap of the OTSC deployment device. The lesion and SRH will be captured into the cap and the OTSC will be deployed by rotating the handle and thereby compressing the bleeding lesion and surrounding tissue for mechanical hemostasis. If initial deployment is unsuccessful due to technical factors or if hemostasis is not achieved, a second deployment will be allowed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Over-the-scope hemoclipping device</intervention_name>
    <description>A endoscopic entrapment of tissue for control of bleeding or other applications.</description>
    <arm_group_label>Over-the-scope hemoclipping device</arm_group_label>
    <other_name>OVESCO clip</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard endoscopic treatment</intervention_name>
    <description>Standard therapy includes injection of dilute epinephrine, thermal coagulation with multipolar electrocautery (MPEC) probe, and/or hemoclips.</description>
    <arm_group_label>Standard endoscopic treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent from the patient or a surrogate.

          -  Clinical evidence of severe UGIB.

          -  Presence of a benign appearing peptic ulcer, post-Endoscopic mucosal resection (EMR)
             ulcer, anastomotic ulcer, Dieulafoy's lesion, or UGI post-polypectomy induced ulcer
             with some SRH on endoscopy.

          -  Severe bleeding, refractory bleeding, or recurrent bleeding.

          -  Life expectancy of at least 30 days based on lack of severe or terminal comorbidity as
             judged by the generalist or subspecialist caring for the patient.

        Exclusion Criteria:

          -  Patients who are do-not-resuscitate (DNR) that is not reversible, uncooperative,
             refuse to participate, or are unable to give consent personally or through a
             surrogate.

          -  Active GI malignancy, under treatment but not in remission.

          -  Acute hypovolemic shock that is unresponsive to transfusion of 5 or more units of red
             blood cells (RBC's) or requires continuous intravenous vasopressor infusion for blood
             pressure support.

          -  ASA (American Society of Anesthesiology) class V, moribund, or with a very poor
             prognosis and expected survival &lt;30 days.

          -  Severe coagulopathy or thrombocytopenia despite attempted reversal with transfusion of
             blood products (e.g persistent International Normalized Ratio [INR] &gt;2.0, platelet
             count &lt;20,000, a Partial Thromboplastin Time [PTT] greater than 2x upper limit of
             normal).

          -  Absolute contraindication to urgent endoscopy (such as suspected perforated viscus,
             peritonitis, or unstable cardiopulmonary status).

          -  Stricture of the esophagus or pylorus that can not be dilated or precludes passage of
             a 12 mm diameter endoscope and/or GI endoscope with the large hemoclipping
             device-Ovesco.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dennis M Jensen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dennis M Jensen, MD</last_name>
    <phone>310-268-3569</phone>
    <email>djensen@mednet.ucla.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kwanmanus N Suvanamas, BS</last_name>
    <phone>310-478-3711</phone>
    <phone_ext>43324</phone_ext>
    <email>ksuvanamas@mednet.ucla.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>VA Greater Los Angeles Healthcare System</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dennis M Jensen, MD</last_name>
      <phone>310-268-3569</phone>
      <email>dennis.jensen@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Kwanmanus N Suvanamas, BS</last_name>
      <phone>310-478-3711</phone>
      <phone_ext>43324</phone_ext>
      <email>kwanmanus.suvanamas@va.gov</email>
    </contact_backup>
    <investigator>
      <last_name>Dennis M Jensen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dennis M Jensen, MD</last_name>
      <phone>310-268-3569</phone>
      <email>djensen@mednet.ucla.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kwanmanus N Suvanamas, BS</last_name>
      <phone>310-478-3711</phone>
      <phone_ext>43324</phone_ext>
      <email>ksuvanamas@mednet.ucla.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Dennis M Jensen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Laine L, Jensen DM. Management of patients with ulcer bleeding. Am J Gastroenterol. 2012 Mar;107(3):345-60; quiz 361. doi: 10.1038/ajg.2011.480. Epub 2012 Feb 7. Review.</citation>
    <PMID>22310222</PMID>
  </reference>
  <reference>
    <citation>Camus M, Jensen DM, Kovacs TO, Jensen ME, Markovic D, Gornbein J. Independent risk factors of 30-day outcomes in 1264 patients with peptic ulcer bleeding in the USA: large ulcers do worse. Aliment Pharmacol Ther. 2016 May;43(10):1080-9. doi: 10.1111/apt.13591. Epub 2016 Mar 22.</citation>
    <PMID>27000531</PMID>
  </reference>
  <reference>
    <citation>Nishiyama N, Mori H, Kobara H, Rafiq K, Fujihara S, Kobayashi M, Oryu M, Masaki T. Efficacy and safety of over-the-scope clip: including complications after endoscopic submucosal dissection. World J Gastroenterol. 2013 May 14;19(18):2752-60. doi: 10.3748/wjg.v19.i18.2752.</citation>
    <PMID>23687412</PMID>
  </reference>
  <reference>
    <citation>Mönkemüller K, Peter S, Toshniwal J, Popa D, Zabielski M, Stahl RD, Ramesh J, Wilcox CM. Multipurpose use of the 'bear claw' (over-the-scope-clip system) to treat endoluminal gastrointestinal disorders. Dig Endosc. 2014 May;26(3):350-7. doi: 10.1111/den.12145. Epub 2013 Jul 16.</citation>
    <PMID>23855514</PMID>
  </reference>
  <reference>
    <citation>Jayaraman V, Hammerle C, Lo SK, Jamil L, Gupta K. Clinical Application and Outcomes of Over the Scope Clip Device: Initial US Experience in Humans. Diagn Ther Endosc. 2013;2013:381873. doi: 10.1155/2013/381873. Epub 2013 Jul 14.</citation>
    <PMID>23935261</PMID>
  </reference>
  <reference>
    <citation>Haito-Chavez Y, Law JK, Kratt T, Arezzo A, Verra M, Morino M, Sharaiha RZ, Poley JW, Kahaleh M, Thompson CC, Ryan MB, Choksi N, Elmunzer BJ, Gosain S, Goldberg EM, Modayil RJ, Stavropoulos SN, Schembre DB, DiMaio CJ, Chandrasekhara V, Hasan MK, Varadarajulu S, Hawes R, Gomez V, Woodward TA, Rubel-Cohen S, Fluxa F, Vleggaar FP, Akshintala VS, Raju GS, Khashab MA. International multicenter experience with an over-the-scope clipping device for endoscopic management of GI defects (with video). Gastrointest Endosc. 2014 Oct;80(4):610-22. doi: 10.1016/j.gie.2014.03.049. Epub 2014 Jun 5.</citation>
    <PMID>24908191</PMID>
  </reference>
  <reference>
    <citation>Chan SM, Chiu PW, Teoh AY, Lau JY. Use of the Over-The-Scope Clip for treatment of refractory upper gastrointestinal bleeding: a case series. Endoscopy. 2014 May;46(5):428-31. doi: 10.1055/s-0034-1364932. Epub 2014 Feb 6.</citation>
    <PMID>24505017</PMID>
  </reference>
  <reference>
    <citation>Jensen DM, Ohning GV, Kovacs TO, Ghassemi KA, Jutabha R, Dulai GS, Machicado GA. Doppler endoscopic probe as a guide to risk stratification and definitive hemostasis of peptic ulcer bleeding. Gastrointest Endosc. 2016 Jan;83(1):129-36. doi: 10.1016/j.gie.2015.07.012. Epub 2015 Aug 28.</citation>
    <PMID>26318834</PMID>
  </reference>
  <reference>
    <citation>Jensen DM, Kovacs TO, Jutabha R, Machicado GA, Gralnek IM, Savides TJ, Smith J, Jensen ME, Alofaituli G, Gornbein J. Randomized trial of medical or endoscopic therapy to prevent recurrent ulcer hemorrhage in patients with adherent clots. Gastroenterology. 2002 Aug;123(2):407-13.</citation>
    <PMID>12145792</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2016</study_first_submitted>
  <study_first_submitted_qc>February 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2017</study_first_posted>
  <last_update_submitted>February 22, 2017</last_update_submitted>
  <last_update_submitted_qc>February 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Upper GI hemorrhage</keyword>
  <keyword>Stigmata of recent hemorrhage</keyword>
  <keyword>Diverticular Hemorrhage</keyword>
  <keyword>Ulcers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Gastrointestinal Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

